Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 6
2011 6
2012 2
2013 1
2014 8
2015 9
2016 11
2017 10
2018 11
2019 11
2020 4
2021 1
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28848656

83 results

Results by year

Filters applied: . Clear all
Page 1
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.
Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli V, Nasti G, Nappi A, Botti G, Tatangelo F, Chicchinelli N, Montrone M, Sebastio A, Guarino T, Simone G, Graziano P, Chiarazzo C, Maggio G, Longhitano L, Manusia M, Cartenì G, Nappi O, Micheli P, Leo L, Rossi S, Cassano A, Tommaselli E, Giordano G, Sponziello F, Marino A, Rinaldi A, Romito S, Muda AO, Lorusso V, Leo S, Barni S, Grimaldi G, Aieta M. Martinelli E, et al. ESMO Open. 2017 Feb 20;1(6):e000086. doi: 10.1136/esmoopen-2016-000086. eCollection 2016. ESMO Open. 2017. PMID: 28848656 Free PMC article.
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio AM, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G. Ciardiello F, et al. Ann Oncol. 2014 Sep;25(9):1756-1761. doi: 10.1093/annonc/mdu230. Epub 2014 Jun 18. Ann Oncol. 2014. PMID: 24942275 Free article.
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, Nappi A, Bordonaro AR, Rachiglio M, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E; CAPRI-GOIM investigators. Ciardiello F, et al. Ann Oncol. 2016 Jun;27(6):1055-1061. doi: 10.1093/annonc/mdw136. Epub 2016 Mar 21. Ann Oncol. 2016. PMID: 27002107 Free article. Clinical Trial.
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C. Bennouna J, et al. JAMA Oncol. 2019 Jan 1;5(1):83-90. doi: 10.1001/jamaoncol.2018.4465. JAMA Oncol. 2019. PMID: 30422156 Free PMC article. Clinical Trial.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. Heinemann V, et al. Lancet Oncol. 2014 Sep;15(10):1065-75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31. Lancet Oncol. 2014. PMID: 25088940 Clinical Trial.
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Zaatar A, Guan Z, Masood N, Srimuninnimit V, Yau T, Gibbs P, Wang X, Doval DC, Oh ST, Shim BY, Gorospe C, Wang HM, Sirachainan E, Hill A, Suh KW, Beier F, Chatterjee S, Lim R. Cheng AL, et al. Clin Colorectal Cancer. 2017 Jun;16(2):e73-e88. doi: 10.1016/j.clcc.2016.08.005. Epub 2016 Sep 7. Clin Colorectal Cancer. 2017. PMID: 27780749 Free article. Clinical Trial.
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Carrato A, et al. Eur J Cancer. 2017 Aug;81:191-202. doi: 10.1016/j.ejca.2017.04.024. Epub 2017 Jun 19. Eur J Cancer. 2017. PMID: 28633089 Free article. Clinical Trial.
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Normanno N, Esposito Abate R, Lambiase M, Forgione L, Cardone C, Iannaccone A, Sacco A, Rachiglio AM, Martinelli E, Rizzi D, Pisconti S, Biglietto M, Bordonaro R, Troiani T, Latiano TP, Giuliani F, Leo S, Rinaldi A, Maiello E, Ciardiello F; CAPRI-GOIM Investigators. Normanno N, et al. Ann Oncol. 2018 Jan 1;29(1):112-118. doi: 10.1093/annonc/mdx417. Ann Oncol. 2018. PMID: 28950295 Free article. Clinical Trial.
83 results